Biopsy results alone may not fully capture the risk of grade group 1 prostate cancer, experts warn, highlighting the need for a comprehensive approach to assessment.
Dr. Neal Patel, urologic oncologist and assistant professor of urology at Weill Cornell Medicine, emphasizes that additional factors such as prostate-specific antigen (PSA) levels, cancer stage, and disease volume are critical for accurately evaluating a patient’s risk.
“Biopsy is only a small sampling of the prostate,” Patel explained. “It might not fully predict long-term outcomes. For that reason, we combine it with PSA, stage, and volume of disease to better understand prognosis.”
Active surveillance remains a safe strategy for most men with low-risk disease. However, Patel notes that patients with higher-risk features may require closer monitoring. National guidelines, including those from the American Urological Association and the National Comprehensive Cancer Network, recommend using multiple clinical parameters to stratify risk before making treatment decisions.
While there has been discussion about removing the “cancer” label from grade group 1 diagnoses, Patel cautions that this could be misleading for some patients. “Most men with low-risk prostate cancer benefit from active surveillance, but our study identified a subset with adverse features that could increase the risk of metastasis. This group requires careful evaluation before considering changes to labeling or treatment strategy.”
Patel stressed that personalized treatment decisions are essential. “No single factor—whether biopsy, PSA, or imaging—should determine the course of care. Patients need a full clinical picture, including blood work, imaging, and biopsy details, to make informed decisions.”
He also urged patients to ask questions about state-of-the-art diagnostics, including the role of MRI and targeted biopsies. “Even advanced imaging has limitations. Seeing a multidisciplinary team experienced in prostate cancer is crucial for ensuring accurate diagnosis and appropriate monitoring,” Patel said.
Ultimately, the research underscores the importance of comprehensive risk assessment in men with low-grade prostate cancer, ensuring that surveillance and treatment decisions reflect the full spectrum of clinical information.
READ MORE
Rising Prostate Cancer Risk Highlights Urgent Need for Screening
PSA Test Drives Prostate Cancer Awareness in North Wales
SOX2 Emerges as Critical Driver in Advanced Prostate Cancer Resistance
